ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2134

PEX5 Acts as a Negative Regulator of RANKL-induced Osteoclastogenesis In Vitro and Inflammatory Calvarial Bone Destruction In Vivo

CHONG HYUK CHUNG1, Myeung-Su Lee1, Chang-hoon Lee2, Ju-Young Kim3, Yoon-Hee Cheon4, So Young Eun3 and Gyeung Do Park3, 1Wonkwang University Hospital, Iksan, South Korea, 2Wonkwang University Hospital, Iksan Jeonbuk, South Korea, 3Musculoskeletal and Immune Disease Research Institute, School of Medicine, Wonkwang University, Iksan, Republic of Korea, 4Musculoskeletal and Immune Disease Research Institute, School of Medicine, Wonkwang University, Iksan, Cholla-bukto, Republic of Korea

Meeting: ACR Convergence 2024

Keywords: bone biology, osteoclastogenesis, RANKL

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Peroxisomal biogenesis factor 5 (PEX5) is essential for regulating peroxisome function by recognizing and transporting peroxisome target sequence receptor substrate proteins to peroxisomes. PEX5 defects impair peroxisomal matrix protein uptake, resulting in excessive reactive oxygen species production and delayed bone formation. However, the effects and mechanism of action of PEX5 in regulating bone metabolism via osteoclastogenesis are unknown.We attempted to determine the effects and mechanism of action of PEX5 in regulating bone metabolism via osteoclastogenesis.

Methods: To determine the effect of PEX5 on RANKL-induced osteoclast differentiation and function, we performed TRAP staining, F-actin stating, and bone resorbing assay using PEX5 recombinant protein or siRNA. The intracellular mechanisms responsible for the regulation of osteoclastogenesis of PEX5 were revealed by western blotting and quantitative real-time RT-PCR. Moreover, in vivo test performed in lipopolysaccharide-induced bone loss model and calvarial bone formation model.

Results: By performing gain- and loss-of-function studies, we discovered that PEX5 plays a negative role as a receptor activator of nuclear factor kappa B ligand (RANKL)-induced osteoclastogenesis and bone resorption. During osteoclastogenesis, the knockdown of PEX5 promotes phosphorylation of early signal transducers such as Akt, mitogen activated protein kinase (p38, c-Jun N-terminal kinase, and extracellular signal-regulated kinase), and Bruton’s tyrosin kinase-Phospholipase C gamma2 signaling, resulting in increased mRNA and protein levels of c-Fos and nuclear factor of activated T cells c1. PEX5 depletion strongly induced the expression of osteoclast-specific genes such as OC-stamp, DC-stamp, β3-integrin, osteoclast-associated receptor, ATP6v0d2, and Cathepsin K. Additionally, in vivo, PEX5 reduced lipopolysaccharide-inoculated osteoclastogenesis and bone resorption in mouse calvaria.

Conclusion: We have discovered a novel link between bone-dissolving osteoclasts and PEX5, a critical peroxisome formation regulator. These findings highlight the significance of PEX5 in the regulation of osteoclast formation and suggest that targeting PEX5 could be an effective therapeutic approach for managing bone-related conditions such as osteoporosis.

Supporting image 1

Figure PEX5 ameliorates LPS-induced inflammatory bone loss in vivo. (A) Schematic representation of the experimental setup. (B) Micro-CT reconstruction images (upper) and TRAP staining of whole calvaria (lower). (C) Microarchitecture parameters assessed by micro-CT. (D) Representative images of calvaria coronal section stained by H&E and TRAP. Scale bars, 200 μm (original magnification, ×40). **P < 0.01 and ***P < 0.001 versus PBS group, and #P < 0.05, ##P < 0.01 versus the LPS group.


Disclosures: C. CHUNG: None; M. Lee: None; C. Lee: None; J. Kim: None; Y. Cheon: None; S. Eun: None; G. Park: None.

To cite this abstract in AMA style:

CHUNG C, Lee M, Lee C, Kim J, Cheon Y, Eun S, Park G. PEX5 Acts as a Negative Regulator of RANKL-induced Osteoclastogenesis In Vitro and Inflammatory Calvarial Bone Destruction In Vivo [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/pex5-acts-as-a-negative-regulator-of-rankl-induced-osteoclastogenesis-in-vitro-and-inflammatory-calvarial-bone-destruction-in-vivo/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pex5-acts-as-a-negative-regulator-of-rankl-induced-osteoclastogenesis-in-vitro-and-inflammatory-calvarial-bone-destruction-in-vivo/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology